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Resistance to infection by the facultative intracellular bacterium Listeria monocyto-
genes is mediated byT lymphocytes (1, 2) . The response ofT cells is antigen specific
and results in the activation ofthe microbicidal activity ofmacrophages (3, 4) . IFN-
yand other lymphokines produced by T cells appear to be involved in this activation
of macrophages (5) .
The acquisition of delayed-type hypersensitivity (DTH)' and the focal accumu-
lation of macrophages in infected sites are correlated with resistance to listerial in-
fection (6) . Studies on adoptive transfer ofT cells from Listeria-immune mice indi-
cated that both CD4+ and CD8+ cells were required for DTH (7), macrophage
accumulation (8-10), and optimal protection (7-11), but that, when large numbers
of cells were transferred, CD8 + cells alone were sufficient for resistance to Listeria
(11) . Recently, Mielke et al . (12) showed directly, by in vivo administration of anti-
CD4 and anti-CD8 mAbs, that CD4+ cells were responsible for DTH, whereas
CD8+ cells played the predominant role in protection against Listeria . Furthermore,
they demonstrated that CD8+ cells mediated protection by activating resident mac-
rophages without accumulating blood macrophages at the site ofinfection (13) . Thus,
the expression ofDTH against L . monocytogenes and macrophage accumulation are
attributable to CD4+ cells, whereas protective immunity against Listeria is mainly
due to CD8+ cells (12, 13) . However, in similar studies, Czuprynski et al . (14)
showed the protective effect ofCD4+ cells by demonstrating exacerbation of listeri-
osis characterized by numerous foci of liver necrosis in mice treated with anti-CD4
mAb. The liver was recently found to be the main target organ of Listeria (15) .
In this study, we investigated the roles ofCD4' and CD8+ cells in primary sub-
lethal and lethal infection with L. monocytogenes by examining the effects of in vivo
administration of anti-CD4 and/or anti-CD8 mAb on recovery of bacteria, the lev-
els oftransaminases, and mortality . We also examined the protective effect ofIFN-'Y
in lethally infected mice .
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' Abbreviations used in thispaper 17TH, delayed-type hypersensitivity ;GM glutamic oxaloacetic trans-
aminase ; GPT, glutamic pyruvic transaminase; H-E, hematoxylin-eosin ; rMuIFN-y, recombinant mu-
rine IFN-y ; TSA, trypticase-soy agar; TSB, trypticase-soy broth .
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Materials and Methods
Mice.
￿
Female BALB/c, congenitally athymic BALB/c (nu/nu) mice and their heterozy-
gous littermates were used at the age of 8-10 wk. These mice were obtained from Shizuoka
Laboratory Animal Center (Shizuoka, Japan) and bred in the Laboratory Animal Center
for Biomedical Research, Nagasaki University School of Medicine.
Bacteria.
￿
L. monocytogenes, strain IID 575, originally obtained from the National Institutes
of Health, Bethesda, MD, was provided by Dr. Yoshikawa, Institute of Medical Science, To-
kyo University (Tokyo, Japan). It was kept virulent by successive passages in mice and stored
frozen at -70°C in trypticase-soy broth (TSB) with 20% glycerol. For each experiment, a
sample was thawed and suspended in sterile saline solution for intravenous injection. Recov-
ery of Listeria was assayed by homogenizing livers and spleens in saline solution and plating
10-fold serial dilutions of the homogenates on trypticase-soy agar (TSA) with SRBC. Colo-
nies were counted after incubation for 24 h at 37°C (16). The LD5 values against BALB/c
and BALB/c nu/nu mice were N4 x 10' and N3 x 104 CFU, respectively. BALB/c mice were
treated intravenously with 4-16 x 102 CFU ofbacteria for sublethal infection and 7-8 x 10'
CFU of bacteria for lethal infection. BALB/c nu/nu mice were treated intravenously with 104
CFU of bacteria for sublethal infection.
mAbs.
￿
Anti-L3T4 (C134) mAb, a rat antibody of the IgG2b Ig classproduced by hybrid-
oma GK1 .5 (17), was kindly provided by Dr. Fitch, University ofChicago (Chicago, IL). The
anti-Lyt-2.2 (CD8) mAb used was described previously (18). The titers of anti-L3T4 (CD4)
and anti-Lyt-2 .2 (CD8) mAbs, determined by antibody-mediated complement-dependent
cytotoxicity assay, were both 1 :20,000. These antibodies were used in the form ofascites from
hybridoma-bearing mice. The concentrations of anti-L3T4 (CD4) and anti-Lyt-2.2 (CD8)
mAbs in pooled ascites were 2 .8 and 7 .1 mg/ml, respectively, as determined by protein assay
(Bio-Rad Laboratories, Richmond, CA) and quantitative cellulose acetate electrophoresis.
Complement (C).
￿
Preselected rabbit serum was used as complement.
In Vioo Administration of mAb.
￿
Mice were anesthetized with ether, and 200 Etl of mAb (as-
cites) diluted 1 :8 with MEM was injected intravenously through the retrobulbar venous plexus
(18). We found previously by flow cytometric analysis that single injections (25 JAI of ascites)
of anti-L3T4 (CD4) mAb and anti-Lyt-2.2 (CD8) mAbs resulted in the elimination from
peripheral lymphoid tissues of CD4` cells for ti2 wk and CD8` cells for N6 wk, respectively
(19). Therefore, we injected anti-L3T4 (CD4) mAb at intervals of 2 wk, and anti-Lyt-2.2
(CD8) mAb at intervals of 4 wk. Experiments lasted no more than 60 d. Blocking of the
functions of CD4` cells and CD8' cells in vivo by mAb treatment was monitored by skin
graft rejection in combinations of H-2b mutant strains and C57BL/6 (20).
Recombinant Murine IFN-'Y (rMuIFN--y) and Its Administration to Mice.
￿
rMuIFN-,y was pro-
duced and purified to >95% by Genentech Laboratory (San Francisco, CA) (21). The lot
(No. 4407-47) used was obtained through Drs. Naruse and Satoh (Daiichi Seiyaku Co. Ltd.,
Tokyo, Japan). The antiviral activity of rMuIFN-y was 8.6 x 106 U/ml and the protein con-
centration was 0.98 mg/ml, as determined by the Lowry method. The solution of rMuIFN-y
was diluted with PBS before use. IFN-,y was injected within several hours after inoculation
of bacteria.
Pretreatment ofSpleen Cells with mAb and C.
￿
Spleen cells (5 x 10') were incubated with mAb
in a volume of 200 j.1 for 30 min at 4°C with occasional mixing. They were then pelleted
and resuspended in rabbit complement diluted 1 :10 with MEM, incubated for 30 min at
37°C, and then washed twice. In adoptive transfer experiments, 3 x 10' cells were injected
intravenously.
Measurement of Serum Transaminase.
￿
Serum samples were diluted 1 :5 with distilled water,
and glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT)
were measured with a Clinalyzer RX 40 (Nippon Denshi, Tokyo, Japan).
Histological Examination.
￿
Organs removed from mice were fixed in 10% buffered formal-
dehyde and stained with hematoxylin-eosin (H-E). Gram staining of paraffin sections was
used for detection of bacteria in tissues.Results
Effect of In Vivo Administration ofAnti-L3T4 (CD4) nzAb and/or Anti-Lyt-2.2 (CD8)
mAb on Multiplication andClearanceofBacteria, andLiverCell Necrosis in SublethalListerio-
sis. Injection of 103 CFU of L. monocytogenes into BALB/c mice caused sublethal
listeriosis. To determine the roles of T cell subsets in primary sublethal listeriosis,
we examined the effect of in vivo administration of anti-L3T4 (CD4) mAb, anti-
Lyt-2.2 (CD8) mAb, and a combination of both mAbs on the multiplication and
clearance of the bacteria and liver cell necrosis. The injections of anti-L3T4 (CD4)
mAb and anti-Lyt-2 .2 (CD8) mAb caused selective depletions of CD4+ cells and
CD8+ cells, respectively (see Materials and Methods). As shown in Fig. 1, the num-
berof bacteria recovered from the liver and spleen of the infected mice treated with
MEM (control) reached a peak of -105 CFU on days 2-4 and then decreased to
an undetectable level by day 10. Treatment of mice with anti-L3T4 (CD4) mAb
increased thepeak number ofthebacteria, whereas treatmentwith anti-Lyt-2.2 (CD8)
mAb or a combination of the two mAbs decreased the peak number.
Treatment of mice with anti-L3T4 (CD4) or anti-Lyt-2.2 (CD8) mAb resulted
in clearance of the bacteria, although this was delayed, but treatment with a combi-
nation of the two mAbs blocked bacterial clearance. These results indicated that ei-
ther CD4+ or CD8+ cells were necessary for, and capable of, mediating clearance
of thebacteria. As the delayofbacterial clearancewas significantly greateraftertreat-
ment with anti-Lyt-2.2 (CD8)mAb than aftertreatmentwith anti-L3T4 (CD4) mAb,
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FIGURE 1.
￿
Effects of in vivo administration ofanti-L3T4 (CD4) mAb (*), anti-Lyt-2.2 (CD8)
mAb (A), or a combination of both mAbs (0) on recovery of bacteria from the liver (A) and
spleen (B). (O) MEM control. Female BALB/c mice were injected intravenously with 103 CFU
of L. monocytogenes on day 0, anti-L3T4 (CD4) mAb on days -1, 13, 27, and 41, and anti-Lyt-2.2
(CD8) mAb on days -1 and 27. The number ofListeria recovered from organs of infected mice
on the indicated days was determined by colony formation assay on TSA. Values are means t
SD for groups of three to seven mice and means for groups of two mice. The detection limit
was 1 Log Listeria .1144
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CD8+ cells may be more efficient than CD4+ cells in mediating clearance ofbacte-
ria in sublethal listeriosis.
Serum GOT andGPT are parenchymal cell enzymes commonly used as markers
of liver cell necrosis. The serum transaminase levels were slightly elevated (GOT,
<200 U/ml; GPT, <100 U/ml) in mice treated with MEM (control) after injection
of 103 CFU ofListeria (Fig. 2). Treatment ofmice with anti-L3T4 (CD4) mAb in-
creased the peak levels further, whereas treatment with anti-Lyt-2.2 (CD8) mAb
or both mAbs lowered the levels slightly. Histological examination ofthe liver on
day 4 showed multiple necrotic foci in mice treated with MEM(Fig. 3 A) and larger
and more numerous necrotic foci in mice treated with anti-L3T4 (CD4) mAb.
The increases in the peak numberofbacteria recovered from the liver and spleen,
and in thelevels ofserum transaminases inmice treated with anti-L3T4 (CD4) mAb,
were studied further usingdifferent sized inocula ofListeria for infection. As shown
in Tables I and II, these increases were even clearer in mice infected with a larger
number of bacteria (1.6 x 103 CFU), but were not observed in mice infected with
fewer bacteria (4 x 102 CFU).
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Serum GOT (A) and GPT
Days
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(B) levels in the mice shown in Fig. 1.
Explanations are as for Fig. 1 .SASAKI ET AL .
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FIGURE 3 .
￿
Photomicrographs of the
liver in listeriosis . Specimens were ob-
tained on day4 from a mouse inocu-
lated with a sublethal dose (103 CFU)
(A), and on day3 from amouse inoc-
ulated with a lethal dose (7 x 10 3
CFU) (B) of Listeria, and on day 14
from amouse inoculated with a lethal
dose and rMuIFN- .yon day 0(C). H-
E, x 40 . Multiple necrotic foci (arrows)
are observed in A, multiple small ab-
scesses (stained dark) containing bacte-
rial clusters and neutrophils in diffusely
necrotic liver are seen in B, andnoob-
vious necrotic foci can be seen in C.
Effect of In Vivo Administration of Anti-L3T4 (CD4) mAb and/or Anti-Lyt-2.2 (CD8)
mAb on Mortality, BacterialMultiplication, and Liver Cell Necrosis in Lethal Listeriosis. In-
jection of>7 x 103 CFU ofL. monocytogenes into BALB/c mice caused lethal listeri-
osis ; the mice died after 4-8 d from systemic infection and massive liver necrosis .
We investigated the effect ofin vivo administration of anti-L3T4(CD4)mAb and/or
anti-Lyt-2 .2 (CD8) mAb on survival of these mice with lethal listeriosis (Fig. 4) .
Treatment with anti-L3T4 (CD4) mAb did not prolong survival significantly, but1146-
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TABLE I
Effect of Anti-L3T4 (CD4) mAb on Bacterial Recoveryfrom the Liver and Spleen
of Mice with Sublethal Listeriosis
' Dose of Listeria injected (CFU). Bacteria were recovered from the liver and spleen on day
4 after infection.
treatment with anti-Lyt-2.2 (CD8) mAb, or acombination ofboth mAbs, prolonged
survival markedly.
The effects of these mAbs on multiplication of bacteria in lethal listeriosis were
then investigated. Aftertreatment ofmice with MEM (control)or anti-L3T4(CD4)
mAb, the recovery ofbacteria increased exponentially in the liver and spleen result-
ing in death, whereas after treatment with anti-Lyt-2.2 (CD8) mAb or a combina-
tion of both mAbs, the recovery of bacteria increased to a peak of -10' CFU on
day 3 andthen decreased (Fig. 5). Treatment ofmice with anti-Lyt-2 .2 (CD8) mAb
resulted in clearance of the bacteria by day 40, whereas after treatment with a com-
bination of the two mAbs, the mice remained persistently infected and -103-104
CFU of bacteria were recovered from the liver and spleen for up to at least 60 d
(data not shown).
Increases in the serum levels of transaminases (GOT, >500 U/ml; GPT, >150 U/ml)
were observed as early as day 2 in all mice treated with MEM (control) or mAb
(Fig. 6). After treatment with MEM (control) or anti-L3T4 (CD4) mAb, the levels
ofserum transaminasesincreasedcontinuously until death, whereas aftertreatment
with anti-Lyt-2.2 (CD8) mAb or acombinationof thetwo mAbs, the levels of serum
transaminases increased to a peak on day 3, and then decreased to within the nor-
mal range by day 14. Histopathological examination ofthe liver showed massive ne-
crosis on day 3 in mice treated with MEM (Fig. 3 B) or anti-L3T4 (CD4) mAb.
TABLE II
Effect of Anti-L3T4 (CD4) mAb on Serum Levels of Transaminases in Mice with
Sublethal Listeriosis
` Dose ofLister a injected (CFU), Serum transaminases were measured on day 4 after infection.
Serum transaminase
Transaminase Treatment 4.0 x 102 ' 8 .0 x 102 1 .6 x 10'
U/ml
MEM 93 1 4 163 + 58 175 + 7
GOT
Anti-L3T4 (CD4) mAb 102 ± 1 254 ± 63 1,387 ± 212
MEM 42±4 97±57 100± 16
GPT
Anti-L3T4 (CD4) mAb 48 ± 2 225 t 50 847 ± 82
Organ Treatment
Number
4.0 x 102 `
of bacteria recovered
8.0 x 102 1 .6 x 10'
log CFU
MEM 3.34 t 0.22 5.14 t 0.99 5.56 t 0 .36
Liver
Anti-L3T4 (CD4) mAb 3 .20 t 0.09 6.30 t 0.04 6.50 t 0 .30
MEM 3.20 t 0.22 4.52 t 0.52 4.66 t 0.38
Spleen
Anti-L3T4 (CD4) mAb 3.95 t 0.06 4.41 ± 0.52 5.71 t 0.34ro m
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In mice treated with anti-Lyt-2.2 (CD8) or a combination of the twomAbs, moder-
ate liver necrosis was observed on day 3 followed by recovery by day 14.
These results suggested that CD8+ cells played a role in irreversible multiplica-
tion of the bacteria and massiveliver necrosis, which causes death in lethal listerio-
sis. Adoptive transfer experiments with nude mouse recipients were performed to
confirm this point. Transfer of spleen cells from normal BALB/c mice pretreated
with anti-L3T4 (CD4) mAb and complement, butnot anti-Lyt-2.2 (CD8) mAb and
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FIGURE 4.
￿
Effects of in vivo administration of
anti-L3T4 (CD4)mAb("), anti-Lyt-2.2 (CD8)
mAb (A), or a combination of both mAbs (O)
on mortalityin lethal listeriosis; (O)MEMcon-
trol. Female BALB/c mice were treated intrave-
nously with 7 x 103 Listeria on day 0, anti-L3T4
(CD4) mAbon days -1, 13, and 27,and Lyt-2.2
(CD8)mAbon days -1 and 27. Each groupcon-
sisted of 20 mice.
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FIGURE 5.
￿
Effects of administration of anti-L3T4 (CD4) mAb("), anti-Lyt-2.2 (CD8) mAb
(A), or acombination of both mAbs (0) on multiplication ofLicteria in the liver(A)and spleen
(B)in lethal listeriosis; (O)MEM control. Female BALB/c mice were injected intravenouslywith
7 x 103 CFU of Listeria on day 0, anti-L3T4 (CD4) mAb on days -1, 13, 27, 41, and 55, and
anti-Lyt-2.2 (CD8) mAb on days -1, 27, and 55. Each group consisted of four to six mice.
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Days
FIGURE 6.
￿
SerumGOT (A) andGPT(B) levels in the mice shown in Fig. 5. Explanations are
as for Fig. 5.
complement, killed recipient BALB/c nu/nu mice inoculated with 104 CFU of bac-
teria (Fig. 7).
Effect ofIn Vivo Administration of rMuIFN-y on Mortality, BacterialMultiplication, and
Liver Cell Necrosis in Lethal Listeriosis. In mice with lethal listeriosis that were un-
treated or had been pretreated with anti-L3T4(CD4) mAb, injection of rMuIFN-y
(3 x 104 U/mouse, i.v.) resulted in marked prolongation of survival (Table III and
Fig. 8), decrease in multiplication of bacteria (Fig. 9), and restoration of transami-
nase levels to normal (Fig. 10). Histological examination showed recovery from ne-
crosis in the liver of mice on day 7 after treatment with either MEM (Fig. 3 C) or
anti-L3T4 (CD4) mAb and rMuIFN-y.
FIGURE 7.
￿
Adoptive transfer experiments.
BALB/c nu/nu mice were injected intrave-
nously on day -7 with BALB/c nu/+
spleen cells that hadbeen pretreated with
anti-L3T4 (CD4) mAb (") or anti-Lyt-
2.2 (CD8)mAb(A)andcomplement; (O)
untreated BALB/c nu/nu mice. Recipient
nude mice were injected with 104 CFU of
Listeria on day 0. The LDso against
BALB/c nu/nu mice was -3 x 104 CFU.
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TABLE III
Effect ofAdministration of rMu1FN-y on Mortality in Lethal Listeriosis
Number of mice surviving/number challenged
MEM alone
￿
3 x 102'
￿
3 x 103 ￿3 x 104
0/5
￿
0/5
￿
3/5
￿
5/5
Dose of murine rMuIFN-y injected (U). Female BALB/c mice were injected
intravenously with 7 x 103 CFU of Listeria and rIFN-y in MEM on day 0.
Survival was determined on day 20.
Discussion
In this study, we found that in mice with sublethal listeriosis, CD8+ cells aug-
mented thepeak recovery of bacteria and the extent of liver cell necrosis, and CD4+
cells suppressed this CD8+ cell-mediated augmentation. Treatment of mice with
anti-CD4 mAb increased thepeak recovery of bacteria and thelevels of serum trans-
aminases, whereas treatment with anti-CD8 mAb or a combination of thetwo mAbs
had the reverse effects. These effects were evident in mice treated with higher doses
(0.8-16 x 103) of bacteria. In mice treated with a combination of the two mAbs,
the liver and spleen remained persistently infected (102-104 CFU/organ) after the
initial decrease in the bacterialrecovery. Sincepersistent infection wasalso observed
in BALB/c nu/nu mice inoculated with a sublethal dose of Listeria (unpublished re-
sults and reference 16), the mechanism(s) of resistance to Listeria multiplication in
the persistent infection appears to be Tcell independent. In fact, macrophage-mediated
protection against Listeria was shown to be effective to a significant extent in euthy-
mic mice as well as in nude mice (16). For complete clearance of bacteria, however,
T cells are definitely required (1, 2, 16, and this paper). We demonstrated that either
CD4+ or CD8+ cells were necessary for, and capable of, mediating clearance of the
bacteria. CD8+ cells were more efficient than CD4` cells, but for optimal clearance
both were necessary.
It has been controversial whether CD4+ cells or CD8+ cells are responsible for
protection against Listeria. Previous studieson adoptive transfer oflymphocytes from
immune mice to naive recipients showed that both CD4+ and CD8+ cells were re-
quired for resistance to Listeria (7-11). However, when larger numbers of lympho-
cytes were transferred, CD8+ cells were sufficient for protection (11). Recently,
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FIGURE 8.
￿
Effect ofadministration of rMuIFN-y
on mortality in lethal listeriosis. Female BALB/c
mice were pretreated with either MEM (A) or
anti-L3T4 (CD4) mAb (p) on day -1, and in-
oculated with 7 x 103 CFU ofListeria and rIFN-y
(104 U) on day 0. (O) MEM alone; (") anti-
L3T4 (CD4) mAb alone. Each group consisted
of 10 mice.1150
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FIGURE 9.
￿
Effect of administration ofxMuIFN-.y on multiplication of Listeria in the liver (A)
and spleen (B)in lethal listeriosis. Female BALB/c mice were pretreated with either MEM (A)
or anti-L3T4 (CD4) mAb (Q) on day -1 and then injected intravenously with 7 x 103 CFU
of Listeria and rIFN-.y (104 U) on day 0. (O) MEM alone; (0) anti-L3T4 (CD4) mAb alone.
Each group consisted of four to six mice.
Mielke et al. (12) demonstrated directly, by in vivo administration of anti-CD4 and
anti-CD8 mAb, that CD8i cells play the main role in protection in mice: adminis-
tration of anti-Lyt-2 (CD8) but not anti-L3T4 (CD4) mAb resulted in inhibition
ofbacterial clearance determined at alater stage after infection. On the other hand,
Czuprynski et al. (14) showed that in vivo administration of anti-L3T4 (CD4) mAb
to mice resulted in increased recovery of bacteria and exacerbation of liver necrosis
early (day 3) after inoculation of a sublethal dose of Listeria . Thus, they concluded
that CD4' cells were essential for protection. The present findings in kinetic anal-
yses ofbacterial recovery andthe levels of serumtransaminases were consistent with
all these results and revealed that these findings are not conflicting, but rather reflected
different phases during the course of infection,
We also demonstrated that in lethal listeriosis, treatment of mice with anti-CD8
mAb, or a combination of anti-CD4 and anti-CD8 mAbs, but not anti-CD4 mAb
alone, markedly prolonged survival, and resulted in decrease in recovery of bacteria
after a peak of -108 CFU and in a decrease in the levels of serum transaminases.
These findings indicated that CD8+ cells were responsible for irreversible multipli-
cation of the bacteria and severe liver necrosis causingdeath in lethal listeriosis. In
this regard, it is noteworthy that 95% ofan intravenous inoculum of Listeria is cleared
by the liver and that hepatocytes, rather than macrophages, are the main targets
of Listeria in the liver (15). Hepatocytes are incapable of inactivating the bacteriaFIGURE 10.
￿
Serum GOT (A) and GPT (B) levels in the mice shown in Fig. 9. Explanations
are as for Fig. 9.
intracellularly (15). Our results are consistent with the findings that Listeria-specific
CD8+ CTL are generated from spleen cells derived from infected mice (22). Dur-
ing the course of viral infection, CD8+ CTL are generated against virally infected
target cells, and these CTL have been shown to be important for antiviral defense
(23). However, it is unknown whether the liver damage by CD8+ cells observed in
sublethal andlethal listerial infection represents a relevant mechanism ofantibacte-
rial resistance. The effectsofadministration of anti-CD4 and anti-CD8 mAbs were
evident as early as day 2 after primary sublethal or lethal infection with Listeria .
These findings indicated early involvement of T cells in host defense against pri-
mary listeriosis and are consistent with the findings previously described (2).
We found that administration of rMuIFN-y to mice with lethal listeriosis mark-
edly prolonged survival, and resulted in a decrease in the multiplication of bacteria
and in recovery from liver necrosis in mice treated with either MEM or anti-CD4
mAb. These findings are consistent with previous reports of decreased bacterial re-
covery after administration of rMuIFN-y (24) and the requirement of endogenous
IFN-y forrecovery from Listeria infection (25, 26). The mechanism(s) by whichIFN-y
protects mice against lethal listeriosis is unknown, but several possibilities may be
considered. First, exogenously administered rIFN-y may decrease the multiplica-
tion of bacteria by activating macrophages, subsequently resulting in recovery from
liver cell necrosis. This possibility is consistent with reports that IFN-y activates
macrophages to promote antimicrobial activity in vitro (27, 28) and in vivo (24),
and that macrophages ingest and inactivate Listeria (15, 29), rather than supporting
its growth, as has been generally assumed (15). Second, IFN-'r may exert its effect
by binding to surface receptors and inducing intracellular changes that are unfavor-
able for development ofListeria. This possibility is supported by reports that recep-
tors for IFN-y arepresent on variouscells, includinghepatocytes (30), and that IFN-'r
induces phenotypic and functional alterations (31). Indeed, this mechanism has re-1152
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cently been shown to operate in hepatocytes with malaria parasites (30). These two
mechanisms are not mutually exclusive and could occur simultaneously. Third, IFN-y
may inhibit CD8' cell-mediated cytotoxicity. However, since IFN-'r has so far been
regarded as an essential lymphokine for the proliferation and differentiation of cyto-
toxic T lymphocytes (32, 33), this possibility seems unlikely.
Summary
Studies were made on the effects of in vivo administration of anti-CD4 mAb, anti-
CD8 mAb, or a combination ofboth mAbs on multiplication of bacteria, the levels
of serum transaminases, and mortality in mice infected with Listeria monocytogenes.
Results showed that in sublethal infection, CD8+ cells enhanced the peak of bacte-
rial multiplication and liver cell necrosis, and CD4+ cells suppressed CD8+ cell-me-
diated enhancement. Results also showed that either CD4+ or CD8+ cells were nec-
essary for, and capable of, mediating clearance of the bacteria. CD8+ cells were
more efficient than CD4+ cells, but for optimal clearance both were necessary.
In lethal listeriosis, treatment of mice with anti-CD8 mAb or a combination of
both anti-CD4 and anti-CD8 mAbs, but not anti-CD4 mAb only, protected mice
from death by decreasing multiplication of bacteria in the liver and spleen after a
peak of -101 CFU, and lowering the elevated serum levels of transaminases. These
findings indicated that CD8+ cells were responsible for causing irreversible systemic
Listeria infection and severe liver necrosis.
In lethal listeriosis, administration of rMuIFN-y markedly prolonged survival by
decreasing multiplication of bacteria and promoting recovery from liver necrosis.
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